ZYLOX-TONBRDG.MED.TECH.H1 (818) - Total Assets
Based on the latest financial reports, ZYLOX-TONBRDG.MED.TECH.H1 (818) holds total assets worth €3.50 Billion EUR (≈ $4.09 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 818 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
ZYLOX-TONBRDG.MED.TECH.H1 - Total Assets Trend (2021–2024)
This chart illustrates how ZYLOX-TONBRDG.MED.TECH.H1's total assets have evolved over time, based on quarterly financial data. See 818 book value for net asset value and shareholders' equity analysis.
ZYLOX-TONBRDG.MED.TECH.H1 - Asset Composition Analysis
Current Asset Composition (December 2024)
ZYLOX-TONBRDG.MED.TECH.H1's total assets of €3.50 Billion consist of 44.3% current assets and 55.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.1% |
| Accounts Receivable | €1.54 Million | 0.0% |
| Inventory | €205.48 Million | 6.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €61.38 Million | 1.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how ZYLOX-TONBRDG.MED.TECH.H1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ZYLOX-TONBRDG.MED.TECH.H1 stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ZYLOX-TONBRDG.MED.TECH.H1's current assets represent 44.3% of total assets in 2024, a decrease from 93.1% in 2021.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2024, down from 43.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 6.0% of total assets.
ZYLOX-TONBRDG.MED.TECH.H1 Competitors by Total Assets
Key competitors of ZYLOX-TONBRDG.MED.TECH.H1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
APT Medical Inc
SHG:688617
|
China | CN¥3.43 Billion |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.02 Billion |
ZYLOX-TONBRDG.MED.TECH.H1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.77 | 3.85 | 3.85 |
| Quick Ratio | 5.16 | 3.38 | 3.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.54 Billion | €1.02 Billion | €1.02 Billion |
ZYLOX-TONBRDG.MED.TECH.H1 - Advanced Valuation Insights
This section examines the relationship between ZYLOX-TONBRDG.MED.TECH.H1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.87 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | 2.3% |
| Total Assets | €3.45 Billion |
| Market Capitalization | $700.41 Million USD |
Valuation Analysis
Below Book Valuation: The market values ZYLOX-TONBRDG.MED.TECH.H1's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ZYLOX-TONBRDG.MED.TECH.H1's assets grew by 2.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
The table below shows the annual total assets of ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €3.45 Billion ≈ $4.04 Billion |
+2.28% |
| 2023-12-31 | €3.38 Billion ≈ $3.95 Billion |
+3.75% |
| 2022-12-31 | €3.25 Billion ≈ $3.80 Billion |
+0.17% |
| 2021-12-31 | €3.25 Billion ≈ $3.80 Billion |
-- |
About ZYLOX-TONBRDG.MED.TECH.H1
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People's Republic of China and internationally. The company offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and in… Read more